SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma

NCT07749859 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Advanced Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Retlirafusp alfa Injection, apatinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences